Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
138 hedge funds and large institutions have $2.53B invested in Blueprint Medicines in 2017 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 51 increasing their positions, 40 reducing their positions, and 14 closing their positions.
107% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 14
39% more capital invested
Capital invested by funds: $1.81B → $2.53B (+$715M)
33% more call options, than puts
Call options by funds: $3.51M | Put options by funds: $2.63M
28% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 40
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
11% more funds holding
Funds holding: 124 → 138 (+14)
0.85% more ownership
Funds ownership: 91.9% → 92.75% (+0.85%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$30.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.7M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$18.3M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$16.4M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$16.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$31.2M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$20.4M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$18.6M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$15.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$15.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
151
Prelude Capital Management
New York
| – | -$12K | -235 | Closed |
|
152
Creative Planning
Overland Park,
Kansas
| – | -$5K | -100 | Closed |
|
BPMC Hedge Fund Activity: Q3 2017 in Review
138 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2017, worth a combined $2.53B — up 39% from $1.81B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new BPMC positions and 14 closed out — a net gain of 15 holders — while 51 added to existing stakes and 40 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $30.3M. The largest seller was BVF Inc, cutting an estimated $31.2M.
- 138 institutional investors held Blueprint Medicines (BPMC) as of Q3 2017, up from 124 in Q2 2017.
- Funds reported $2.53B of Blueprint Medicines stock for Q3 2017, up 39% quarter-over-quarter.
- 29 funds opened new Blueprint Medicines positions in Q3 2017 and 14 closed out, a net change of +15 holders.
- The largest Blueprint Medicines buyer in Q3 2017 was Fidelity Investments, an estimated $30.3M added.
- The largest Blueprint Medicines seller in Q3 2017 was BVF Inc, an estimated $31.2M sold.
Based on aggregated 13F filings for Q3 2017.